5 edition of mTOR pathway and mTOR inhibitors in cancer therapy found in the catalog.
mTOR pathway and mTOR inhibitors in cancer therapy
V. A. PolunovskiД
Includes bibliographical references and index.
|Statement||Vitaly A. Polunovsky, Peter J. Houghton, editors|
|Series||Cancer drug discovery and development, Cancer drug discovery and development|
|LC Classifications||RC270.8 .M83 2010|
|The Physical Object|
|Pagination||xii, 301 p. :|
|Number of Pages||301|
|ISBN 10||1603272704, 1603272712|
|ISBN 10||9781603272704, 9781603272711|
|LC Control Number||2010930694|
mTOR Pathway and mTOR Inhibitors in Cancer Therapy provides an up-to-date survey of the rapidly advancing field of cancer therapy. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment targeted : Copertina rigida. In certain cancers the mTOR pathway is more active. Mammalian target of rapamycin (mTOR) inhibitors are used in treatment of renal cancer and is being studied for use in other types of cancers. More benefits are being seen when MTOR inhibitors are combined with other chemotherapy agents. Managing Side Effects of mTOR Inhibitors (Temsirolimus) The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that is active in cell division, growth, proliferation, resistance to hypoxic stress, and apoptosis Abnormalities in the mTOR signaling pathway have been implicated in various pathologies, including renal cancer.5File Size: KB. The latest in the series of monographs Cancer Drug Discovery and Development is mTOR Pathway and mTOR Inhibitors in Cancer cin was first employed as an antifungal agent in humans and named for the Polynesians (Papa Nui) who inhabited Easter Island, where it was isolated from the bacteria Streptomyces hygroscopidcus. The target of rapamycin (TOR) is a serine/threonine Cited by: 9.
mTOR inhibitors are a class of drugs that inhibit the mechanistic target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases (PIKKs). mTOR regulates cellular metabolism, growth, and proliferation by forming and signaling through two protein complexes, mTORC1 and mTORC2. The PI3K/AKT/mTOR constitutes an important pathway downstream of growth factor tyrosine kinase receptors, thus regulating a plethora of biological processes as angiogenesis, proliferation, metabolism, survival, and differentiation .Accumulating evidences indicate, therefore, that alterations in the PI3K/AKT/mTOR axis play critical and multifaceted role in cancer pathogenesis and by: 4. The molecular mechanisms underlying the quality and quantity of life extension appear to sometimes be orthogonal. For example, while resveratrol has continued to prove beneficial in reducing obesity, it has had less efficacy in extending lifespan. On the other hand, rapamycin and the chemically similar rapalogs extend lifespan across genera of life from yeast, to nematodes, to : Sage Arbor. The mTOR pathway is probably the main pathway in humans and other animals that drives growth. That is, the accumulation of mass and adding mass to make an organism bigger by both making more cells.
This pilot phase II trial studies how well nanoparticle albumin-bound rapamycin works in treating patients with cancer that as has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced cancer) and that has an abnormality in a protein called mechanistic target of rapamycin (mTOR). Head and neck cancer is the sixth most common type of Cancer worldwide. Since conventional treatment regimens are nonselective and are associated with systemic toxicities, intense investigations focus on molecular targeted therapy with high selectivity and low adverse effects. mTOR signaling pathway has been found to be activated in head and neck cancer, making it attractive for targeted by: The treatment of advanced gynecologic cancers remains palliative in most of cases. Although systemic treatment has entered into the era of targeted drugs the antitumor efficacies of current therapies are still limited. In this context there is a great need for more active treatment and rationally designed targeted therapies. The PI3K/AKT/mTOR is a signaling pathway in mammal cells that Cited by: Pris: kr. Inbunden, Skickas inom vardagar. Köp mTOR Pathway and mTOR Inhibitors in Cancer Therapy av V A Polunovsky, Peter J Houghton på
Data, chance & probability
Licensing Act, 1904
The rime of the ancyent marinere
Irish case for communism
Dicks diverting dialogues
An essay on the pernicious practice of impressing seamen into the Kings service
Postage stamps of Great Britain
The once and future king.
Turks and Christians: A Solution of the Eastern Question
Daviess County, Missouri, slave schedules for 1850 & 1860 (plus index)
366 Emergency Ideas for Every Day of the Year
Models in inorganic biochemistry
WETWARD, WHOA! WILD WEST C.O.W
Grasshopper Green and the meadow-mice
The latest in the series of monographs Cancer Drug Discovery and Development is mTOR Pathway and mTOR Inhibitors in Cancer cin was first employed as an antifungal agent in humans and named for the Polynesians (Papa Nui) who inhabited Easter Island, where it was isolated from the bacteria Streptomyces hygroscopidcus.
The mTOR pathway and mTOR inhibitors in cancer therapy book of rapamycin (TOR) mTOR pathway and mTOR inhibitors in cancer therapy book a serine/threonine kinase Cited by: 9. mTOR Pathway and mTOR Inhibitors in Cancer Therapy provides an up-to-date survey of the rapidly advancing field of cancer therapy.
Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment – targeted : Hardcover. The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2).
mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of by: mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy Article Literature Review in Hematology/oncology clinics of North America 26(3), vii June with 34 Reads.
Given the integral role the mTOR pathway plays in cancer growth and proliferation, components of the mTOR pathway have been increasingly viewed as potential therapeutic targets. It has been shown that embryonic knock-out of mTOR is lethal, and homozygous mTOR−/− mice die during embryonic development , .Cited by: mTOR Pathway and mTOR Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development) - Kindle edition by Polunovsky, Vitaly A., Houghton, Peter J.
Download it once and read it on your Kindle device, PC, phones or tablets. Use features like bookmarks, note taking and highlighting while reading mTOR Pathway and mTOR Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development).Manufacturer: Humana.
Lee "mTOR Pathway and mTOR Inhibitors in Cancer Therapy" por disponible en Rakuten Kobo. The main objective of this book is to provide an up-to-date survey of Brand: Humana Press.
The newly developed third generation of mTOR inhibitors can potentially overcome the drug resistance of cancer cells bearing mTOR FRB/kinase domain mutation; that is, FRB domain mutations (mTOR. In this review, we discuss mTOR biology and regulation, the mode of action of mTOR inhibitors as anti-cancer agents, and current clinical evidence supporting the use of rapamycin-like mTOR inhibitors in cancer treatment.
mTOR Pathway and mTOR Inhibitors in Cancer Therapy provides an up-to-date survey of the rapidly advancing field of cancer therapy. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment – targeted therapy.
Derivatives of rapamycin such as temsirolimus and everolimus, which are allosteric inhibitors of mTORC1, have become established as effective anticancer agents in specific tumor types, including breast cancer, kidney cancer, and pancreatic neuroendocrine tumors. 8 Nevertheless, the efficacy of these “rapalogs” is modest, is often limited to Cited by: 3.
Numerous efforts have been made to develop PI3K/AKT/mTOR targeted therapies for cancer treatment. Various drugs such as PI3K, AKT, or mTOR kinase inhibitors are in clinical development and allosteric inhibitors of mTOR complex 1 (mTORC1), temsirolimus and everolimus, have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treating Cited by: MTORC1: A signaling integration node involved in cell growth --The regulation of the IGF-1/mTOR pathway by the p53 tumor --mTOR signaling in angiogenesis --mTORC1 signaling and hypoxia --mTOR signaling in glioblastoma: lessons learned from bench to bedside --mTOR and cancer therapy: general principles --mTOR and cancer therapy: clinical.
Houghton P.J. () mTOR and Cancer Therapy: General Principles. In: Polunovsky V., Houghton P. (eds) mTOR Pathway and mTOR Inhibitors in Cited by: 2.
Click on the book chapter title to read by: 9. A growing cancer cell divides in two: mTOR inhibitors such as everolimus help regulate cellular processes in cancer. The target of rapamycin (known as mTOR or the mechanistic target of rapamycin) is a protein that tells cells when to grow, divide, and survive.
mTOR often mutates in cancer cells, leading to uncontrolled tumor cell growth. The mammalian Target of Rapamycin (mTOR) pathway plays an essential role in sensing and integrating a variety of exogenous cues to regulate cellular growth and metabolism, in both physiological and pathological conditions.
mTOR functions through two functionally and structurally distinct multi-component complexes, mTORC1 and mTORC2, which interact with each other and with several.
Read "mTOR Pathway and mTOR Inhibitors in Cancer Therapy" by available from Rakuten Kobo. The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreo Brand: Humana Press. TY - BOOK. T1 - mTOR inhibitors in cancer treatment.
AU - Platanias, Leonidas C. PY - /12/1. Y1 - /12/1. N2 - Increased understanding of the mTOR signaling pathway in relation to malignant cells has prompted extensive efforts to develop new therapeutic by: 1.
MTOR Pathway and mTOR Inhibitors in Cancer Therapy provides an up-to-date survey of the rapidly advancing field of cancer therapy. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy.
Too much mTOR activation is associated with a large number pdf human diseases, including cancer, obesity, pdf, type 2 diabetes, depression, and neurodegeneration [2, 10].
mTOR is associated with cancer and indeed, it increases angiogenesis (via HIF-1a), a process through which new blood vessels form from pre-existing vessels, helping tumors : Puya Yazdi.The Mechanistic or Mammalian Target of Rapamycin (mTOR) is a major signaling pathway in eukaryotic download pdf belonging to the P13K-related kinase family of the serine/threonine protein kinase.
It has been established that mTOR plays a central role in cellular processes and implicated in various cancers, diabetes, and in the aging process with very poor prognosis.
Inhibition of the mTOR pathway in Cited by: 5.Title: mTOR Pathway and mTOR Inhibitors as Ebook for Cancer Therapy VOLUME: 8 ISSUE: 8 Author(s):Paolo Baldo, Sara Cecco, Elisa Giacomin, Renzo Lazzarini, Barbara Ros and Stefano Marastoni Affiliation:Hospital Pharmacy Centro di Riferimento Oncologico of Aviano, Via Franco Gallini, 2, Aviano (PN), Italy.
Keywords:mtor, cancer therapy, signal-tranduction, pathway, rapamycin.